z-logo
open-access-imgOpen Access
Direct inhibition of the transforming growth factor‐β pathway by protein‐bound polysaccharide through inactivation of Smad2 signaling
Author(s) -
Ono Yoshihiro,
Hayashida Tetsu,
Konagai Ayano,
Okazaki Hiroshi,
Miyao Kazuhiro,
Kawachi Shigeyuki,
Tanabe Minoru,
Shinoda Masahiro,
Jinno Hiromitsu,
Hasegawa Hirotoshi,
Kitajima Masaki,
Kitagawa Yuko
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.02133.x
Subject(s) - transforming growth factor , smad , signal transduction , cancer research , smad2 protein , cell growth , biology , cd44 , mapk/erk pathway , epithelial–mesenchymal transition , microbiology and biotechnology , cell , downregulation and upregulation , gene , biochemistry
Transforming growth factor‐β (TGF‐β) is involved in the regulation of cell proliferation, differentiation, and apoptosis and is associated with epithelial–mesenchymal transition (EMT). Inhibition of the TGF‐β pathway is an attractive strategy for the treatment of cancer. We recently screened for novel TGF‐β inhibitors among commercially available drugs and identified protein‐bound polysaccharide (PSK) as a strong inhibitor of the TGF‐β‐induced reporter activity of 3TP‐lux, a TGF‐β1‐responsive luciferase reporter. Protein‐bound polysaccharide is used as a non‐specific immunostimulant for the treatment of gastric and colorectal cancers in Japan. The anticancer activity of this agent may involve direct regulation of growth factor production and enzyme activity in tumors in addition to its immunomodulatory effect. Although several clinical studies have shown the beneficial therapeutic effects of PSK on various types of tumors, its mechanism of action is not clear. In the present study, Western blot analysis showed that PSK suppressed the phosphorylation and nuclear localization of the Smad2 protein, thereby suggesting that PSK inhibits the Smad and MAPK pathways. Quantitative PCR analysis showed that PSK decreased the expression of several TGF‐β pathway target genes. E‐cadherin and vimentin immunohistochemistry showed that PSK suppressed TGF‐β1‐induced EMT, and FACS analysis showed that PSK inhibited the EMT‐mediated generation of CD44 + /CD24 − cells. These data provide new insights into the mechanisms mediating the TGF‐β‐inhibiting activity of PSK and suggest that PSK can effectively treat diseases associated with TGF‐β signaling. ( Cancer Sci 2012; 103: 317–324)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here